Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
599 clinical trials found
Clinical trials

ROCKET-ASCEND

A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) (NCT05882877)

No longer recruiting

ROSETTA

Red Blood Cell Transfusion in ECMO - a feasibility trial (NCT05814094)

No longer recruiting

RPC01-3201

INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (NCT03440372)

Currently recruiting

RPC01-3202

A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (Celgene 3202) (NCT03440385)

Currently recruiting

RPC01-3203

A Phase 3, multicentre, randomized, double-blind, placebo controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s disease (RPC01-3203) (NCT03464097)

Currently recruiting

RPC01-3204

A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease (NCT03467958)

Currently recruiting

S-BAN

Evaluating the effectiveness of sodium butyrate for treatment of anorexia nervosa in individuals aged 16 and over - an open-label proof of concept study (ACTRN12624000368538p)

Currently recruiting

SABR-COMET 10

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10) (NCT03721341)

No longer recruiting

SABR-COMET 3

A phase III randomised controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) of Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer. (NCT03862911)

Currently recruiting

SAD-AF

Selective Serotonin Reuptake Inhibitors And Depression in Atrial Fibrillation (SAD-AF) (ACTRN12623000227695p)

Currently recruiting

SAFER-TAVI

Secondary Access - FEmoral or radial in Transcatheter Aortic Valve Implantation TAVI? (NCT06284837)

Currently recruiting

SALSA

Stopping Antiviral Therapy in People with HBeAg-negative CHB and Low Surface Antigen (Trial Not Registered)

Currently recruiting

SatisfACtion CAAA802A12101

SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mHSPC) and in men with heavily pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC) with or without prior 177Lu-labelled PSMA-targeted radioligand therapy

This is an open label, phase I/II, multi-center study in adult participants with metastatic hormone sensitive prostate cancer (mHSPC) and with metastatic castration resistant prostate cancer (mCRPC) who have received prior anti-cancer treatment and have a positive 68Ga-PSMA-11 PET scan. The purpose of this study is to learn if the study drug, [225Ac]Ac-PSMA-R2, is safe and tolerable, and has anti-tumor activity in treated patients.
Currently recruiting

SEAFARER

Subscalp EEG Augmentation For Accuracy and Reliability in Epilepsy Reviews (ACTRN12625000231448)

Currently recruiting

SeaLAND

An ALLG phase 3 randomised trial of Selinexor and Lenalidomide versus lenalidomide maintenance post Autologous stem cell transplant for patients with Newly Diagnosed multiple myeloma (SeaLAND) (ACTRN12620000291987)

Currently recruiting

SEARCH

Screening for Early onset Amyloid Related Cerebral Hemorrhage

Currently recruiting

Seelos SLS-005

A double-blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia (NCT05490563)

Currently recruiting

SEL002

A Phase 2b Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Behavioural Variant Fronto-temporal Dementia (ACTRN12620000236998)

Currently recruiting

SEL003

A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Progressive Supranuclear Palsy (ACTRN12620001254987)

Currently recruiting

SELECT

A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Chronic Drug-Resistant Temporal Lobe Epilepsy (ACTRN12623000446662)

Currently recruiting
23 24 25 26 27